Spectral AI to Participate in Benchmark’s 12th Annual Discovery One-on-One Conference
- Spectral AI received a substantial contract from the U.S. Government valued at up to $149 million in September 2023.
- The company has received total U.S. Government awards since 2019 to more than $246.0 million.
- Multiple clinical studies have validated the efficacy of the DeepView® System in assessing whether a burn wound or DFU will heal on its own or will require medical intervention to do so.
- None.
DALLAS, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, today announced that it will participate in the Benchmark 12th Annual Discovery One-on-One Conference being held on December 7, 2023 in New York City.
Management will participate in 1x1 meetings throughout the day with institutional investors. For more information on the Benchmark 12th Annual Discovery One-on-One Conference, or to schedule a one-on-one meeting, please contact your Benchmark representative or visit the Conference Website: Click here.
Spectral AI Company Highlights
- Spectral AI’s DeepView® System provides clinicians with an objective and immediate assessment of a wound’s healing potential through the application of proprietary AI algorithms, with initial applications involving patients with burns and diabetic foot ulcers (DFU).
- In September 2023, Spectral AI received the largest contract in its history from the U.S. Government valued at up to
$149 million to support the clinical validation and FDA clearance of the DeepView® System for burn wound assessment. Together with previous contracts, this brings total U.S. Government awards to the Company since 2019 to more than$246.0 million . - Multiple clinical studies have validated the efficacy of the DeepView® System in assessing - within seconds - whether a burn wound or DFU will heal on its own or will require medical intervention to do so.
- The Company expects to submit applications for FDA, UKCA, and CE mark approval for the DeepView® System DFU indication and 3D wound measurement in 2024, and for FDA and CE mark approval for the burn indication in 2025.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com.
Forward Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
| Contacts: | |
| Investors: | |
| Spectral AI | The Equity Group |
| Vince Capone | Devin Sullivan, Managing Director |
| General Counsel | dsullivan@equityny.com |
| ir@spectral-ai.com | |
| Conor Rodriguez, Analyst | |
| crodriguez@equityny.com | |
| Media: | |
| Russo Partners | |
| David Schull | Guillermo Ruiz, M.D., Ph.D. |
| Russo Partners | Russo Partners |
| (858) 717-2310 | (646) 218-4604 |
| david.schull@russopartnersllc.com | guillermo.ruiz@russopartnersllc.com |
FAQ
What is Spectral AI, Inc.'s ticker symbol?
What is the DeepView® System?
What was the value of the U.S. Government contract received by Spectral AI in September 2023?
What approvals does Spectral AI expect for its DeepView® System in 2024 and 2025?
